Virtual Screening and Biological Evaluation of Inhibitors Targeting the XPA-ERCC1 Interaction

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Barakat, Khaled H ^a,b   Jordheim, Lars P ^c,d   Perez Pineiro, Rolando ^a   Wishart, David ^a   Dumontet, Charles ^c,d   Tuszynski, Jack A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b FAYOUM UNIVERSITY   (Egypt)

^c UNIVERSITÉ DE LYON   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AB 00027849; AB 0026258; ANTINEOPLASTIC AGENT; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NERI 01; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DNA REPAIR; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EXCISION REPAIR; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SENSITIZATION; SURFACE PLASMON RESONANCE; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION;

CELL LINE, TUMOR; CULTURE MEDIA; DNA; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; LIGANDS; MODELS, CHEMICAL; MODELS, MOLECULAR; MODELS, STATISTICAL; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; SOLUBILITY; STATIC ELECTRICITY; ULTRAVIOLET RAYS; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 84871265063     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051329     Document Type: Article

References (57)

1. Rouillon C, White MF, (2011) The evolution and mechanisms of nucleotide excision repair proteins. Res Microbiol 162: 19-26.
2. Nouspikel T, (2009) DNA repair in mammalian cells: Nucleotide excision repair: variations on versatility. Cell Mol Life Sci 66: 994-1009.
3. Koberle B, Tomicic MT, Usanova S, Kaina B, (2010) Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 1806: 172-182.
4. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, et al. (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316.
5. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, et al. (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13: 3855-3859.
6. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, et al. (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18: 522-528.
7. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, et al. (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167-172.
8. Shahzad MM, Lopez-Berestein G, Sood AK, (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12: 148-152.
9. Yang Z, Roginskaya M, Colis LC, Basu AK, Shell SM, et al. (2006) Specific and efficient binding of xeroderma pigmentosum complementation group A to double-strand/single-strand DNA junctions with 3′- and/or 5′-ssDNA branches. Biochemistry 45: 15921-15930.
10. Batty DP, Wood RD, (2000) Damage recognition in nucleotide excision repair of DNA. Gene 241: 193-204.
11. Rosenberg E, Taher MM, Kuemmerle NB, Farnsworth J, Valerie K, (2001) A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res 61: 764-770.
12. Tsodikov OV, Ivanov D, Orelli B, Staresincic L, Shoshani I, et al. (2007) Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J 26: 4768-4776.
13. Koberle B, Masters JR, Hartley JA, Wood RD, (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273-276.
14. Welsh C, Day R, McGurk C, Masters JR, Wood RD, et al. (2004) Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110: 352-361.
15. Barakat KH, Torin Huzil J, Luchko T, Jordheim L, Dumontet C, et al. (2009) Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. J Mol Graph Model 28: 113-130.
16. Jiang H, Yang LY, (1999) Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res 59: 4529-4534.
17. Barakat KH, Mane JY, Tuszynski JA (2011) Virtual Screening: An Overview on Methods and Applications. In: Liu LA, Wei D, Li Y, Lei H, editors. Handbook of Research on Computational and Systems Biology: Interdisciplinary Applications: IGI.
18. Barakat K, H, Tuszynski J (2011) Virtual Screening for DNA Repair Inhibitors. In: Storici F, editor. DNA Repair- On the Pathways to Fixing DNA Damage and Errors. 1 ed. Rijeka: InTech.
19. Chimiotheque Nationale library. http://chimiotheque-nationale.enscm.fr/?lang=en. 2012 Last accessed November 15.
20. Philippopoulos M, Lim C, (1999) Exploring the dynamic information content of a protein NMR structure: comparison of a molecular dynamics simulation with the NMR and X-ray structures of Escherichia coli ribonuclease HI. Proteins 36: 87-110.
21. Lin JH, Perryman AL, Schames JR, McCammon JA, (2003) The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme. Biopolymers 68: 47-62.
22. Schames JR, Henchman RH, Siegel JS, Sotriffer CA, Ni H, et al. (2004) Discovery of a novel binding trench in HIV integrase. J Med Chem 47: 1879-1881.
23. Markowitz MN, Gotuzzo F, Mendo F, Ratanasuwan W, Kovacs C, et al. (2006) Potent antiviral effect of MK-0518, novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naive HIV-1 infected patients. 16th International AIDS Conference, Toronto, Canada.
24. Babakhani A, Talley TT, Taylor P, McCammon JA, (2009) A virtual screening study of the acetylcholine binding protein using a relaxed-complex approach. Comput Biol Chem 33: 160-170.
25. Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, et al. (2008) Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc Natl Acad Sci U S A 105: 17278-17283.
26. Durrant JD, McCammon JA, (2010) Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. Comput Biol Chem 34: 97-105.
27. Durrant JD, Urbaniak MD, Ferguson MA, McCammon JA, (2010) Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4′-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness. J Med Chem 53: 5025-5032.
28. Barakat K, Mane J, Friesen D, Tuszynski J, (2010) Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. J Mol Graph Model 28: 555-568.
29. Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC, (2010) Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol 17: 725-734.
30. Barakat K, Issac B, Stepanova M, Tuszynski J (2010) Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: Comparing the wild type to the R248Q mutant. Poster presented at the 17th Canadian Symposium on Theoretical Chemistry (Edmonton, AB, Canada).
31. Ni H, Sotriffer CA, McCammon JA, (2001) Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: a molecular dynamics study. J Med Chem 44: 3043-3047.
32. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
33. Shoichet BK, Stroud RM, Santi DV, Kuntz ID, Perry KM, (1993) Structure-based discovery of inhibitors of thymidylate synthase. Science 259: 1445-1450.
34. Schneider G, Bohm HJ, (2002) Virtual screening and fast automated docking methods. Drug Discov Today 7: 64-70.
35. Abagyan R, Totrov M, (2001) High-throughput docking for lead generation. Curr Opin Chem Biol 5: 375-382.
36. Bodenreider C, Beer D, Keller TH, Sonntag S, Wen D, et al. (2009) A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem. 395: 195-204.
37. Lakowicz JR (1999) Principles of fluorescence spectroscopy, 2nd edn. Kluwer Academic, New York.
38. Lakowicz JR, Weber G, (1973) Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules.Biochemistry 12: 4161-4170.
39. Ware WR, (1962) Oxygen Quenching of Fluorescence in Solution: an Experimental Study of the Diffusion Process J Phys Chem 66: 455-458.
40. Sarasin A, (1999) The molecular pathways of ultraviolet-induced carcinogenesis. Mutat Res 428: 5-10.
41. de Vries A, van Oostrom CT, Hofhuis FM, Dortant PM, Berg RJ, et al. (1995) Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377: 169-173.
42. Cummings M, Higginbottom K, McGurk CJ, Wong OG, Koberle B, et al. (2006) XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72: 166-175.
43. Nagao A, Zhao X, Takegami T, Nakagawa H, Matsui S, et al. (2008) Multiple shRNA expressions in a single plasmid vector improve RNAi against the XPA gene. Biochem Biophys Res Commun 370: 301-305.
44. http://www.schrodinger.com/.Last accessed on 2012 November 15.
45. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, et al. (2007) PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 35: W522-525.
46. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
47. Lin JH, Perryman AL, Schames JR, McCammon JA, (2002) Computational drug design accommodating receptor flexibility: the relaxed complex scheme. J Am Chem Soc 124: 5632-5633.
48. Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
49. Shao J, Tanner SW, Thompson N, Cheatham TE, (2007) Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms. Journal of Chemical Theory and Computation. 3: 2312.
50. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
51. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174.
52. Kalé L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, et al. (1999) NAMD2: Greater Scalability for Parallel Molecular Dynamics. Journal of Computational Physics 151: 283-312.
53. http://www.simulations-plus.com/.Last accessed on 2012 November 15.
54. Welcomme N, Lesieur D, Lespagnol C, Rabaron A, Navarro J, (1978) Chalcones et flavonones derivées de l'acide beta-résorcylique. Déméthylation des dérivés de l'acide diméthoxy-2,4-benzoïque. Annales Pharmaceutiques Françaises 36: 135-138.
55. Routier S, Coudert G, Mérour JY, (2001) Synthesis of Naphthopyrrolo[3,4-c]carbazoles. Tetrahedron Lett 42: 7025-7028.
56. Routier S, Peixoto P, Mérour JY, Coudert G, Dias N, Bailly C, Léonce S, Caignard DH, (2005) Synthesis and biological evaluation of novel naphthocarbazoles as potential anticancer agents, J Med Chem. 48: 1401-1413.
57. Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C, (2005) Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 4: 1268-1276.